AstraZeneca COVID-19 vaccine likely to protect for a year - CEO
BRUSSELS (Reuters) - AstraZeneca's potential coronavirus vaccine <AZN.L> is expected to protect against COVID-19 infection for about a year, the company's managing director told a Belgian radio station on Tuesday.
The British pharmaceutical company has already started trials on people developed by Oxford University. A Phase I study in the UK is expected to end soon and a Phase III study has already started, Pascal Soriot told Bel RTL.
"We believe it will protect for about a year," said Soriot.
AstraZeneca announced on Saturday that it had signed contracts with France, Germany, Italy and the Netherlands for the delivery of up to 400 million doses of the potential vaccine to the European Union.
Agreements have also been made with the United Kingdom and the United States.
"If everything goes well, we will have the results of the clinical studies in August / September. We will produce in parallel. We will be able to deliver from October if everything goes well," said Soriot.
(Reporting by Philip Blenkinsop; Editing by Jason Neely)
Watch the latest videos from Yahoo UK
Skateboarder Danny Leon enjoyed the snow in Madrid
Chrissy Teigen Cuddles Up to John Legend in Nothing But Logo-Coated Gucci Tights
Two Russian tennis players banned for life for match-fixing
AT&T takes $15.5 billion charge on DirecTV, adds more phone customers
Leni Klum Continues to Follow in Mom Heidi's Supermodel Footsteps by Opening Berlin Fashion Week
Bridgerton 's Phoebe Dynevor Reveals This NSFW Scene Was the "Hardest" to Film